• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Eisai 'extremely disappointed' by EMA's decision on Alzheimer's drug

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 30, 2024 at 11:42: AM
via A committee from the European Medicines Agency (EMA) has voted against granting Leqembi (lecanemab) a marketing authorization due to the risk of serious side effects associated with the treatment.

article source
 

<



Similar threads

cafead
Eisai, Biogen&#039;s Leqembi nabs UK nod, but reimbursement remains elusive
Replies
0
Views
33
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eisai and Biogen&#039;s Alzheimer&#039;s med Leqembi turned down in Europe
Replies
0
Views
38
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eisai and Biogen launch Alzheimer&#039;s drug Leqembi in China
Replies
0
Views
24
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA accepts Eisai&#039;s subcutaneous Leqembi filing, sets January 25 decision date
Replies
0
Views
9
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eisai starts rolling submission for injectable version of Alzheimer&#039;s drug with US FDA
Replies
0
Views
55
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote